AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%
BioDelivery Sciences International, Inc.
BDSI Details
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company specializing in developing treatments for those suffering from severe and debilitating chronic illnesses. BDSI uses its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology to develop and commercialize novel medicines that address critical unmet medical needs. BELBUCA (buprenorphine buccal film) for chronic pain and Symproic (naldemedine) for opioid-induced constipation are two of the company's product candidates.
Latest News:
Q3FY21 Results:
Key Risks:
Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation
(Analysis by Kalkine Group)
BDSI Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
The company’s performance in the quarter just gone by was moderate. Further, the company’s is taking relatively higher time to convert its investment in inventories into cash at bank compared to its peers. Further, BDSI's stock price increased 21.50% in the past and trading above 50-day SMA, however 200-day SMA could be a crucial resistance in the stock and 14-day RSI oscillator hovering in a overbought zone at 72.18, implies a potential consolidation from the current trading level.
Considering the uptick in the stock price, current valuation, and technical indicators, we recommend a "Sell" rating on the stock at the current price of USD 3.646, down 1.19%, as of January 25, 2022, 01:59 PM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.